Ignite Creation Date:
2024-07-17 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06476093
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-06-10
Brief Title:
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Sponsor:
The First Peoples Hospital of Lianyungang
Organization:
The First Peoples Hospital of Lianyungang
Study Overview
Official Title:
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer a Single-arm Prospective Exploratory Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer
Detailed Description:
Anlotinib indication Anlotinib is a novel oral multi-target receptor tyrosine kinase inhibitor which has been shown to inhibit tumor growth by suppressing signaling pathways involving angiogenesis and cell proliferation It has been approved by the Chinese National Medical Products Administration as a third-line therapy for NSCLC
SRT indication SRTStereotactic Radiation Therapy is a form of local radiation therapy that delivers high doses of radiation in a limited number of treatments Within Chinese guidelines and consensus it is clearly defined that limited intracranial metastases can be treated with SRT instead of WBRT Whole Brain Radiotherapy achieving comparable or even superior efficacy while better preserving neurocognitive function
SRT indication SRTStereotactic Radiation Therapy is a form of local radiation therapy that delivers high doses of radiation in a limited number of treatments Within Chinese guidelines and consensus it is clearly defined that limited intracranial metastases can be treated with SRT instead of WBRT Whole Brain Radiotherapy achieving comparable or even superior efficacy while better preserving neurocognitive function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None